↓ Skip to main content

Dove Medical Press

From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting

Overview of attention for article published in Lung Cancer: Targets and Therapy, June 2023
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#35 of 135)
  • Good Attention Score compared to outputs of the same age (69th percentile)

Mentioned by

twitter
5 X users

Readers on

mendeley
4 Mendeley